Johnson & Johnson's IL-23 inhibitor Tremfya beat Novartis AG's IL-17A inhibitor Cosentyx on a long-term, 48-week primary endpoint in psoriasis in the Phase III ECLIPSE study, but was not superior on a range of secondary measures.
First-in-class Tremfya (guselkumab), partnered with MorphoSys AG, was approved for psoriasis in the US in mid-2017 and is in...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)